Use of <sup>177</sup>Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer : Joint statement of the Austrian Society of Nuclear Medicine and Theranostics and the Austrian Society of Urology and Andrology.

Wien Klin Wochenschr · 2025 · PMC12137475 · PMID 40464929

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

5.6 months), yet OS did not reach statistical significance in the trial.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.